The FDA Jan. 21 approved  Horizon Therapeutics' drug, Tepezza, the first drug designed to treat thyroid eye disease.

AstraZeneca plans to invest $520 million in its manufacturing site in Dunkirk, France, over the next five years and create roughly 150 jobs, Bloomberg reported. 

Amazon filed to trademark its "Amazon Pharmacy" brand in Canada, the United Kingdom and Australia, a sign that it may be planning to expand its business outside the U.S., CNBC reported. 

Ten hospitals and health systems posted job listings seeking pharmacy leaders in the last week.

The World Health Organization warned that unless governments motivate drugmakers to develop new antibiotics, drug-resistant infections could kill 10 million people annually by 2050, The New York Times reported.  

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. 

GlaxoSmithKline is temporarily halting nationwide production of some of its Excedrin products, ABC affiliate WSYR reported. 

Both CVS and Walgreens demanded that the other be excluded from CareSource, Ohio's largest Medicaid provider, causing 272 pharmacies to be cut from the network, Ohio Medicaid Director Maureen Corcoran told The Columbus Dispatch. 

A Philadelphia judge shaved $1.2 billion off the amount Johnson & Johnson has to pay in a lawsuit over the marking of its antipsychotic drug, Risperdal, The New York Times reported. 

Civica Rx is a nonprofit generic drug company created in 2018 by seven major health systems to combat drug shortages and rising drug costs. 

The FDA is a government agency tasked with protecting public health by making sure prescription drugs are safe and efficient. 

The FDA has approved Novo Nordisk's drug, Ozempic, to be used to reduce the risk of cardiovascular events such as heart attack or stroke in adults with Type 2 diabetes who have a known history of heart disease. 

Medicare Part B covers drugs that are administered by healthcare providers, such as infused or injected cancer drugs. 

Medicare Part D covers pharmacy-dispensed drugs, primarily oral drugs and some self-injectables, such as insulin. 

Axia Pharmaceutical is recalling all lots of its sterile drug products because it says it cannot guarantee they are sterile. 

Insys Therapeutics, the first drugmaker to go bankrupt after opioid litigation, won court approval for its bankruptcy plan Jan. 16, The Wall Street Journal reported.

BioMarin Pharmaceutical may price its gene therapy treatment for hemophilia even higher than Zolgensma, Novartis' gene therapy drug that is currently the world's most expensive, The Wall Street Journal reported. 

CVS Health is offering emergency prescription refills for its customers in Puerto Rico who were affected by recent earthquakes, the company said Jan. 16.

KRS Global Biotechnology, a Boca Raton, Fla.-based drug compounding facility, filed for Chapter 11 bankruptcy after "unforeseen business circumstances," the Sun Sentinel reported Jan. 16.

GlaxoSmithKline hasn't made plans to pursue an initial public offering on the consumer health company it created with Pfizer, a top executive told Bloomberg a day after Pfizer's CEO said they plan to offer an IPO in the next three to four years.